Literature DB >> 12034819

Analysis of inhibitory action of modified U1 snRNAs on target gene expression: discrimination of two RNA targets differing by a 1 bp mismatch.

Peng Liu1, Amy Gucwa, Mary Louise Stover, Emily Buck, Alexander Lichtler, David Rowe.   

Abstract

The modified U1 snRNA gene can suppress expression of a target transgene. In the present study, its potential utility to inhibit a dominant negative/gain of function mutation is explored. Using a green fluorescent protein (GFP) target gene, inhibition was achieved in all cells transduced with U1antiGFP directed at multiple sites within GFP. Using a chloramphenicol acetyltransferase (CAT) target gene, inhibition was not increased by increasing the hybridization domain from 10 to 16 bp or when a site in an upstream exon or intron was targeted. To determine if a U1 anti-target design could discriminate between two transcripts that differ by a 1-2 bp mismatch, GFPtpz and GFPsaph were chosen as targets because they share sequence homology except for three regions where a 1, 2 or 3 bp mismatch exists. The results demonstrated that U1antiGFP correctly reduced its cognate GFP expression by >90% and therefore U1 anti-target constructs are able to discriminate a 1 or 2 bp mismatch in their target mRNA. Thus, these U1 anti-target constructs may be effective in a strategy of somatic gene therapy for a dominant negative/gain of function mutation due to the discreteness of its discrimination. It may complement other anti-target strategies to reduce the cellular load of a mutant transcript.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034819      PMCID: PMC117199          DOI: 10.1093/nar/30.11.2329

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  43 in total

1.  Four new cases of lethal osteogenesis imperfecta due to glycine substitutions in COL1A1 and genes. Mutations in brief no. 152. Online.

Authors:  M Mottes; M Gomez Lira; F Zolezzi; M Valli; V Lisi; P Freising
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

2.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

3.  A compensatory base change in U1 snRNA suppresses a 5' splice site mutation.

Authors:  Y Zhuang; A M Weiner
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

4.  The U1 small nuclear RNA-protein complex selectively binds a 5' splice site in vitro.

Authors:  S M Mount; I Pettersson; M Hinterberger; A Karmas; J A Steitz
Journal:  Cell       Date:  1983-06       Impact factor: 41.582

5.  U1 small nuclear RNA genes are located on human chromosome 1 and are expressed in mouse-human hybrid cells.

Authors:  E Lund; C Bostock; M Robertson; S Christie; J L Mitchen; J E Dahlberg
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

6.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

7.  A catalogue of splice junction sequences.

Authors:  S M Mount
Journal:  Nucleic Acids Res       Date:  1982-01-22       Impact factor: 16.971

8.  A single-base change at a splice site in a beta 0-thalassemic gene causes abnormal RNA splicing.

Authors:  R Treisman; N J Proudfoot; M Shander; T Maniatis
Journal:  Cell       Date:  1982-07       Impact factor: 41.582

9.  Effect of differential polyadenylation and cell growth phase on dihydrofolate reductase mRNA stability.

Authors:  V Noé; C J Ciudad; L A Chasin
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

10.  A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells.

Authors:  W G Jiang; D Grimshaw; J Lane; T A Martin; R Abounader; J Laterra; R E Mansel; R Abounder
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

View more
  7 in total

1.  Modified U1 snRNA suppresses expression of a targeted endogenous RNA by inhibiting polyadenylation of the transcript.

Authors:  Peng Liu; Mark Kronenberg; Xi Jiang; David Rowe
Journal:  Nucleic Acids Res       Date:  2004-03-03       Impact factor: 16.971

2.  AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i.

Authors:  A Koornneef; R van Logtenstein; E Timmermans; L Pisas; B Blits; X Abad; P Fortes; H Petry; P Konstantinova; T Ritsema
Journal:  Gene Ther       Date:  2011-04-07       Impact factor: 5.250

3.  Use of modified U1 snRNAs to inhibit HIV-1 replication.

Authors:  R Sajic; K Lee; K Asai; D Sakac; D R Branch; C Upton; A Cochrane
Journal:  Nucleic Acids Res       Date:  2006-12-08       Impact factor: 16.971

Review 4.  The reciprocal regulation between splicing and 3'-end processing.

Authors:  Daisuke Kaida
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-03-28       Impact factor: 9.957

5.  A U1i RNA that Enhances HIV-1 RNA Splicing with an Elongated Recognition Domain Is an Optimal Candidate for Combination HIV-1 Gene Therapy.

Authors:  Olivier Del Corpo; Ryan P Goguen; Camille M G Malard; Aïcha Daher; Susan Colby-Germinario; Robert J Scarborough; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-18       Impact factor: 8.886

6.  Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA.

Authors:  Puri Fortes; Yolanda Cuevas; Fei Guan; Peng Liu; Sara Pentlicky; Stephen P Jung; Maria L Martínez-Chantar; Jesús Prieto; David Rowe; Samuel I Gunderson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

7.  Requirements for gene silencing mediated by U1 snRNA binding to a target sequence.

Authors:  Xabi Abad; Maria Vera; Stephen P Jung; Evelyn Oswald; Inés Romero; Vaibhav Amin; Puri Fortes; Samuel I Gunderson
Journal:  Nucleic Acids Res       Date:  2008-02-24       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.